Biohaven secures US$600 million in non-dilutive funding to enhance its cash runway and clinical programs, while also reducing R&D spending by 60%. This funding will aid its evolution into a multi-franchise biopharma.
Amount Raised
$600 Million
Round Type
Debt Financing
New HavenBiotechnologyHealth CareTherapeuticsInvestors
Description
Biohaven recently secured a US$600 million non-dilutive funding agreement with Oberland Capital and significantly reduced R&D spending by about 60%. This combination aims to extend its cash runway and support its clinical programs in neurology, immunology, and oncology. The funding highlights Biohaven’s strategy to evolve into a multi-franchise biopharma while limiting shareholder dilution. It also raises questions about how the R&D cuts will affect the pace of key trials.
Quick answer
Biohaven raised $600 Million in a Debt Financing round, dated March 1, 2026. Investors: Oberland Capital. Biohaven is based in New Haven, Connecticut, United States.
- How much did Biohaven raise?
- Biohaven raised $600 Million in a Debt Financing round on March 1, 2026.
- Who invested in Biohaven?
- Oberland Capital is named as investors in this round.
- What does Biohaven do?
- Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including..
- Where is Biohaven based and how big is it?
- Biohaven is based in New Haven, Connecticut, United States. Fundz records about 280 employees.
- Who are the decision-makers at Biohaven?
- Fundz holds 4 contacts at Biohaven, including the CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Biohaven that raised within 45 days of this round, from Fundz verified event records.
- Sparian Biosciences raised $15M (Grant) on April 13, 2026.
- Sidewinder Therapeutics raised $137M (Series B) on April 8, 2026.
- Marvel Biosciences raised an undisclosed amount (Funding Round) on April 7, 2026.
- TransCode Therapeutics raised $20M (Funding Round) on April 7, 2026.
- TippingPoint Biosciences raised $4.5M (Seed) on March 31, 2026.
- Denali Therapeutics raised $200M (Debt Financing) on March 31, 2026.
Who to call at Biohaven, and when
A new round usually means Biohaven is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Biohaven raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Biohaven, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Biohaven. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Biohaven raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Biohaven raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.